Starling Oncology, Inc. STLN revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Starling Oncology, Inc. reported revenue across 5 products and services; the largest, Health Care Specialty Pharmacy, was $269M (+49.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Health Care Specialty Pharmacy$269Mshare n/a+49.6% yoy
- Health Care Patient Service$229Mshare n/a+11.8% yoy
- Fee For Service$149Mshare n/a+9.0% yoy
- Capitated Revenue$80.5Mshare n/a+17.2% yoy
- Clinical Research Trials And Other Revenue$4.56Mshare n/a-47.0% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Health Care Specialty Pharmacy$87.5Mshare n/a+77.6% yoy
- Health Care Patient Service$59.1Mshare n/a+11.3% yoy
- Fee For Service$32.2Mshare n/a-9.6% yoy
- Capitated Revenue$26.9Mshare n/a+53.9% yoy
- Clinical Research Trials And Other Revenue$813Kshare n/a-60.2% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.